ANAHEIM,
Calif., July 25, 2023 /PRNewswire/ -- Beckman
Coulter, a clinical diagnostics leader, today revealed for the
first time in North America
the DxI 9000 Access Immunoassay Analyzer, addressing clinical
laboratory demands for speed, reliability, reproducibility,
quality, and menu expansion. The DxI 9000 Analyzer has shown
capability to develop increasingly sensitive and clinically
relevant assays enabling the platform to keep pace with tomorrow's
testing requirements as healthcare providers and pharmaceutical
companies take aim at evermore challenging diseases.
We believe that there is more clinical data
available from a patient's blood sample than is currently
accessible.
According to Zivjena Vucetic, M.D., Ph.D., Chief Medical Officer
and Senior Vice President, Medical & Scientific Affairs,
President, Beckman Coulter Diagnostics, "We believe that there is
more clinical data available from a patient's blood sample than is
currently accessible. Early system evaluations and conversations
with users suggest that the DxI 9000 Analyzer opens up new
opportunities to quantify trace amounts of key biomarkers in blood
samples. The implications extend throughout healthcare systems. For
example, in Alzheimer's disease, adding a highly accurate and more
patient-friendly testing option to current diagnostic solutions,
with the goal of providing alternative options to PET-imaging or a
lumbar puncture, amplifies the impact of new pharmaceutical
therapies and ultimately improves patient outcomes."
Ray Divilley, Chief Medical Officer, Mayo University Hospital,
Ireland, was an early evaluator of
the DxI 9000 Analyzer added, "With the DxI 9000, Beckman Coulter
has successfully produced a platform that addresses today's
laboratories needs for speed, accuracy, and reliability. Based on
our use and evaluation of the system in our lab, we were able to
get actionable results back quicker to doctors and ultimately
patients as they consider treatment options."
Recently, Beckman Coulter Diagnostics and Fujirebio, a leader in
neurological markers and In Vitro Diagnostic (IVD) manufacturing,
announced a new partnership combining their respective immunoassay
strengths to support therapeutic development, clinical trials,
reimbursement, and routine clinical adoption in the field of
neurodegenerative diseases. Initial assay development efforts will
focus on the recently introduced DxI 9000 Access Immunoassay
Analyzer and the widespread installed base of Access Family
Immunoassay Analyzers.
"This collaboration with Beckman Coulter will help accelerate
the deployment of our portfolio of new, novel neurodegenerative
biomarkers to laboratories and clinicians around the world. As the
pre-eminent provider of leading-edge immunoassays to the
diagnostics industry, this partnership is an important step to
speed the transition of these markers from research to clinical use
in all major geographies and to bring a higher standard of care to
patients and their families in the battle against this debilitating
disease," stated Goki Ishikawa, President & CEO, Fujirebio
Holdings, Inc.
In addition to advancing diagnostics capabilities, the DxI 9000
excels in improving clinical laboratory operations.
ZeroDaily Maintenance highlights the embedded innovations that
drive the DxI 9000 Analyzer's uptime performance. Beta users attest
to ZeroDaily Maintenance redefining their workday with no daily
maintenance requirements, thereby reducing annual maintenance
routines by up to 96%.
Building on Beckman Coulter's workflow and automation
leadership, PrecisionVision Technology is unmatched in its ability
to inspect, identify and prevent erroneous reporting in real time.
PrecisionVision automated safeguards include tube identification,
cap detection, tip check, sample aspiration, and delivery, residual
wash volume, and substrate volume. Each check reduces the risk of
reporting flawed data and increases system reliability and
reproducibility.
The DxI 9000 Access Immunoassay Analyzer is currently available
in most countries worldwide.
Additional Resources
- Link to DxI 9000 Access Immunoassay Analyzer media kit
- Follow and connect with Beckman Coulter Diagnostics
via LinkedIn, Twitter, and Facebook.
About Beckman Coulter. Inc.
A global leader in
advanced diagnostics, Beckman Coulter has challenged convention to
elevate the diagnostic laboratory's role in improving patient
health for more than 80 years. Our mission is to Relentlessly
Reimagine Healthcare, One Diagnosis at a Time – and we do this
by applying the power of science, technology and the passion and
creativity of our teams. Our diagnostic solutions are used in
complex clinical testing, and are found in hospitals, reference
laboratories and physician office settings around the globe. We
exist to deliver smarter, faster diagnostic solutions that move the
needle forward from what's now to what's next. We seek to
accelerate care with an extensive clinical menu, scalable lab
automation technologies, insightful clinical informatics, and
optimize lab performance services. Beckman Coulter is part of the
Danaher Corporation (NYSE:DHR) family of global science and
technology companies. Headquartered in Brea, Calif., it has more than 11,000 global
team members.
©2023 Beckman Coulter. All rights reserved. Beckman Coulter, the
stylized logo, and the Beckman Coulter product and service marks
mentioned herein are trademarks or registered trademarks of Beckman
Coulter, Inc. in the United States
and other countries. 2023-11982
View original content to download
multimedia:https://www.prnewswire.com/news-releases/beckman-coulters-dxi-9000-immunoassay-analyzer-with-increased-assay-development-sensitivity-makes-first-north-american-appearance-at-2023-aacc-301884651.html
SOURCE Beckman Coulter, Inc.
